Table 2. Univariate and multivariate Cox regression analyses for the training cohort.
| Variable | Univariate analysis | Multivariate analysis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| RFS | OS | RFS | OS | ||||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||||
| Age, y (≤50 vs. >50) | 0.92 (0.590–1.440) | 0.720 | 1.418 (0.928–2.166) | 0.107 | NA | NA | NA | NA | |||
| Gender (male vs. female) | 1.286 (0.775–2.132) | 0.330 | 1.160 (0.724–1.859) | 0.538 | NA | NA | NA | NA | |||
| HBV | 0.710 (0.447–1.129) | 0.148 | 0.761 (0.486–1.192) | 0.233 | NA | NA | NA | NA | |||
| AFP, ng/mL (≤20 vs. >20) | 3.811 (2.565–5.664) | <0.001 | 2.786 (1.911–4.061) | <0.001 | 2.245 (1.447–3.482) | <0.001 | 1.813 (1.177–2.790) | <0.001 | |||
| Tumor number (single vs. multiple) | 1.964 (1.346–2.866) | <0.001 | 1.617 (1.131–2.310) | <0.001 | 1.709 (1.127–2.590) | 0.012 | 1.367 (0.929–2.011) | 0.113 | |||
| Tumor size, cm (≤3 vs. >3) | 2.438 (1.664–3.573) | <0.001 | 2.011 (1.407–2.873) | <0.001 | 1.894 (1.264–2.839) | 0.002 | 1.458 (0.987–2.155) | 0.049 | |||
| Cirrhosis | 0.9293 (0.469–1.841) | 0.834 | 0.737 (0.384–1.411) | 0.357 | NA | NA | NA | NA | |||
| CTP (A vs. B) | 0.7377 (0.103–5.295) | 0.762 | 1.996 (0.274–14.530) | 0.495 | NA | NA | NA | NA | |||
| MELD (≤4.81 vs. >4.81) | 0.693 (0.473–1.015) | 0.059 | 0.797 (0.555– 1.143) | 0.217 | NA | NA | NA | NA | |||
| ALBI | 0.8 | 0.2 | NA | NA | NA | NA | |||||
| 2 | 1.132 (0.774–1.656) | 0.523 | 1.358 (0.945–1.951) | 0.098 | NA | NA | NA | NA | |||
| 3 | 0.882 (0.215–3.621) | 0.862 | 2.355 (0.566–9.791) | 0.239 | NA | NA | NA | NA | |||
| ALT, U/L (≤40 vs. >40) | 1.209 (0.794–1.842) | 0.377 | 1.142 (0.765–1.705) | 0.515 | NA | NA | NA | NA | |||
| AST, U/L (≤40 vs. >40) | 1.410 (0.867–2.293) | 0.166 | 1.056 (0.664–1.677) | 0.819 | NA | NA | NA | NA | |||
| Γ-GT, U/L (≤60 vs. >60) | 1.492 (1.012–2.198) | 0.043 | 1.409 (0.976–2.034) | 0.067 | 1.020 (0.649–1.604) | 0.932 | 0.986 (0.635–1.530) | 0.948 | |||
| TBIL, μmol/L (≤17.1 vs. >17.1) | 0.870 (0.275–2.751) | 0.812 | 1.612 (0.655–3.968) | 0.299 | NA | NA | NA | NA | |||
| ALB, g/L (≤43.2 vs. >43.2) | 1.399 (0.895–2.186) | 0.141 | 0.9748 (0.627–1.516) | 0.910 | NA | NA | NA | NA | |||
| PLR (≤125.28 vs. >125.28) | 2.132 (1.393–3.262) | <0.001 | 1.656 (1.118–2.454) | 0.012 | 0.736 (0.422–1.282) | 0.279 | 0.738 (0.450–1.212) | 0.230 | |||
| NLR (≤3 vs. >3) | 2.250 (1.497–3.382) | <0.001 | 1.884 (1.441–3.706) | <0.001 | 1.433 (0.877–2.342) | 0.151 | 1.166 (0.750–1.814) | 0.495 | |||
| PNI (≤52.21 vs. >52.21) | 0.593 (0.318–1.107) | 0.101 | 0.568 (0.313–1.032) | 0.063 | 1.109 (0.556–2.213) | 0.770 | 0.816 (0.422–1.578) | 0.546 | |||
| SII (≤324.55 vs. >324.55) | 5.717 (3.391–9.640) | <0.001 | 3.676 (2.275–5.938) | <0.001 | 4.072 (2.271–7.304) | <0.001 | 2.619 (1.501–4.571) | <0.001 | |||
OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh; MELD, Model for End-Stage Liver Disease; ALB, albumin; ALT, alanine aminotransferase; AST, aspartic transaminase; γ-GT, γ-glutamyl transpeptidase; TBIL, total bilirubin; NLR, neutrophil lymphocyte ratio; SII, systemic immune inflammatory index; PLR, platelet lymphocyte ratio; PNI, prognostic nutritional index.